ATHA Stock Overview A late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. More details
Risk Analysis + 1 more risk
See All Risk Checks Capture your thoughts, links and company narrative
Athira Pharma, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Athira Pharma Historical stock prices Current Share Price US$0.54 52 Week High US$4.30 52 Week Low US$0.41 Beta 3 1 Month Change -12.58% 3 Month Change 21.99% 1 Year Change -77.97% 3 Year Change -95.63% 5 Year Change n/a Change since IPO -96.83%
Recent News & Updates
High number of new directors Dec 17
Athira Pharma Receives Notification Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement for Continued Listing on The Nasdaq Global Select Market Oct 20
Athira Pharma Receives Notification Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement for Continued Listing on The Nasdaq Global Select Market Oct 19
Athira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative Diseases Sep 18
Price target decreased by 46% to US$4.00 Sep 05
Athira Pharma, Inc. Announces Topline Results from Phase 2/3 Lift-AD Clinical Trial of Fosgonimeton for Mild-to-Moderate Alzheimer's Disease Sep 04 See more updates
High number of new directors Dec 17
Athira Pharma Receives Notification Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement for Continued Listing on The Nasdaq Global Select Market Oct 20
Athira Pharma Receives Notification Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement for Continued Listing on The Nasdaq Global Select Market Oct 19
Athira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative Diseases Sep 18
Price target decreased by 46% to US$4.00 Sep 05
Athira Pharma, Inc. Announces Topline Results from Phase 2/3 Lift-AD Clinical Trial of Fosgonimeton for Mild-to-Moderate Alzheimer's Disease Sep 04
Athira Pharma Announces Last Patient Completed Lift-Ad Clinical Trial of Fosgonimeton in Mild-To-Moderate Alzheimer’s Disease Jul 09
New major risk - Financial position Jul 01
Independent Chairwoman of the Board recently bought US$100k worth of stock Jun 27
Athira Pharma, Inc. Announces Proposed Settlement of Stockholder Derivative Action May 18
Athira Pharma, Inc. Appoints Javier San Martin, M.D., as Chief Medical Officer Apr 15
Athira Pharma, Inc. Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer's Disease Apr 11
Athira Pharma, Inc., Annual General Meeting, May 23, 2024 Apr 10
New minor risk - Market cap size Mar 13
Will Athira Pharma (NASDAQ:ATHA) Spend Its Cash Wisely? Feb 16
Athira Pharma, Inc. Announces Publication in Frontiers in Neuroscience Highlighting Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS) Feb 09 Athira Pharma, Inc. Announces Hans Moebius Retires as Chief Medical Officer
Athira Pharma, Inc. Announces Hans Moebius Retires as Chief Medical Officer Jan 08
Price target increased by 23% to US$9.25 Nov 18
Athira Pharma, Inc. Presents Preclinical Data Highlighting Fosgonimeton's Neuroprotective Effects Against Amyloid-B-Induced Pathological Alterations and Neuroinflammation in Models of Alzheimer's Disease Nov 17
Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Invest In Growth? Nov 02
New minor risk - Market cap size Aug 20 Athira Pharma, Inc. Appoints Andrew Gengos as Chief Financial Officer
Athira Pharma, Inc. Presents Phase 2 Clinical Data Correlating Improvements in Biomarkers of Neurodegeneration and Neuroinflammation with Improvements in Measures of Cognition and Function in Alzheimer’s Disease Jul 18
CFO & Chief Business Officer recently bought US$192k worth of stock Jun 08
Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Invest In Growth? May 29
Athira Pharma, Inc. Announces the Appointment of Andrew Gengos as Chief Business Officer May 24
Athira Pharma, Inc. Announces CFO Changes May 23
Independent Director recently bought US$60k worth of stock Apr 02
Price target decreased by 33% to US$7.83 Mar 31
Athira Pharma Announces Promotion of Kevin Church to Chief Scientific Officer Feb 01
Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Deliver On Growth Plans? Jan 04
Chief Financial Officer recently bought US$142k worth of stock Jan 01
Athira Pharma, Inc. Announces Publication of Fosgonimeton Preclinical Results in Neurotherapeutics Dec 22
Independent Chairwoman of the Board recently bought US$99k worth of stock Dec 08
Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of ATH-1105 in ALS at the 33rd International Symposium on ALS/MND Dec 06
Price target increased to US$11.75 Nov 16
High number of new and inexperienced directors Nov 16
Athira Pharma Advances Phase 2/3 Lift-Ad Clinical Study of Fosgonimeton in Mild-To Moderate Alzheimer's Patients Following Independent, Unblinded Interim Analysis Oct 18
Price target increased to US$11.75 Oct 18
Athira Alzheimer's drug trial gets monitoring panel nod to continue after efficacy analysis Oct 17
Athira Pharma, Inc. Provides Update on Plans for Ongoing LIFT-AD Clinical Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Patients Sep 07
Athira Pharma GAAP EPS of -$0.65 Aug 15
We're Hopeful That Athira Pharma (NASDAQ:ATHA) Will Use Its Cash Wisely Aug 09
Athira Pharma Presents Data from ACT-AD Phase 2 Proof-of-Concept Clinical Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Patients at the Alzheimer's Association International Conference 2022 Aug 04
Price target decreased to US$15.40 Jun 23
Athira Pharma, Inc. Announces Topline Results from ACT-AD Phase 2 Proof of Concept Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease Jun 23
Athira Pharma: The Market Is Missing A Potential New Alzheimer's Drug Jun 22
Athira Pharma, Inc. Announces New Board Appointments Jun 08
Richard A Kayne Issues Letter to Shareholders of Athira Pharma Inc May 13 Athira Pharma Extends Ongoing Open Label Extension Study for LIFT-AD and ACT-AD Clinical Trials of Fosgonimeton (ATH-1017) for Mild to Moderate Alzheimer’s Disease May 10
Companies Like Athira Pharma (NASDAQ:ATHA) Are In A Position To Invest In Growth May 08
Richard A Kayne Communicates with Athira Pharma Inc May 06
Richard A Kayne Communicates with Athira Pharma Inc May 05
High number of new and inexperienced directors Apr 27 Richard A. Kayne Files an Investor Presentation to Shareholders of Athira Pharma Richard A. Kayne Files an Investor Presentation to Shareholders of Athira Pharma
Richard A. Kayne Provides Information to Shareholders of Athira Pharma Inc Apr 23
Athira Pharma, Inc., Annual General Meeting, May 19, 2022 Apr 06
Athira Pharma, Inc. Doses First Subject in Phase 1 Clinical Trial of HGF/MET Positive Modulator, ATH-1020, an Orally Available Small Molecule for Neuropsychiatric Conditions Apr 05
Independent Chairman of the Board recently bought US$105k worth of stock Apr 02
Richard A. Kayne Sends Provides Information to Shareholders of Athira Pharma Inc Mar 31
Athira Pharma, Inc. Presents Preclinical Data of Fosgonimeton (ATH-1017) and ATH-1020 at the American Society for Experimental Neurotherapeutics (ASENT) Annual Meeting Mar 04
Athira Pharma, Inc. Announces Publication of Phase 1 Results for Fosgonimeton (ATH-1017) in The Journal of Alzheimer's Disease Feb 24
Price target increased to US$39.67 Feb 15
Athira Pharma, Inc. Appoints Grant Pickering to Its Board of Directors Feb 01
Athira Pharma Announces Initiation of Patient Dosing in Shape, a Phase 2 Clinical Trial of ATH-1017 Jan 26
We're Not Very Worried About Athira Pharma's (NASDAQ:ATHA) Cash Burn Rate Jan 11
Price target decreased to US$33.75 Dec 16
High number of new and inexperienced directors Nov 02
Chief Operating Officer exercised options to buy US$485k worth of stock. Aug 22
Independent Chairman of the Board Tadataka Yamada has left the company Aug 11
Independent Chairman of the Board Tadataka Yamada has left the company Aug 05
The Law Offices of Frank R. Cruz Announces the Filing of Securities Class Action on Behalf of Athira Pharma, Inc. Investors Jul 15
Athira Pharma: What, Exactly, Did The CEO Do? Jun 29 Athira Pharma, Inc.(NasdaqGS:ATHA) dropped from Russell 3000E Growth Index
Block & Leviton LLP Files Lawsuit Against Athira Pharma, Inc. for Securities Fraud Jun 26
Athira Pharma falls after the decision to place CEO on temporary leave Jun 17
Athira surges after Jefferies estimated 50% gain on FDA approval for Biogen’s Alzheimer’s therapy Jun 07
We Think Athira Pharma (NASDAQ:ATHA) Can Afford To Drive Business Growth May 24
Athira Pharma, Inc. Announces the Appointment of Barbara Kosacz to its Board of Directors Mar 09
New 90-day low: US$19.29 Mar 05
We're Hopeful That Athira Pharma (NASDAQ:ATHA) Will Use Its Cash Wisely Feb 08
Athira: Early Stage Alzheimer's Therapeutics With An Interesting Approach Jan 11
Here's What Athira Pharma, Inc.'s (NASDAQ:ATHA) Shareholder Ownership Structure Looks Like Dec 18
Athira Pharma, Inc. Appoints of Kelly A. Romano to its Board of Directors Dec 15
Athira Pharma Awarded $15 Million Grant from National Institute on Aging to Support ACT-AD Clinical Trial in Alzheimer’s Disease Dec 10
Athira Pharma nabs research grant of $15M from NIH Dec 08
Athira Pharma Announces Initiation of Patient Dosing for ACT-AD Clinical Trial of ATH-1017, Small Molecule HGF/MET Activator, for Treatment of Mild-to-Moderate Alzheimer’s Disease Dec 02
Athira Pharma reports Q3 results Nov 12 Shareholder Returns ATHA US Pharmaceuticals US Market 7D -1.1% 2.9% 2.8% 1Y -78.0% 8.8% 24.5%
See full shareholder returns
Return vs Market: ATHA underperformed the US Market which returned 24.8% over the past year.
Price Volatility Is ATHA's price volatile compared to industry and market? ATHA volatility ATHA Average Weekly Movement 17.8% Pharmaceuticals Industry Average Movement 10.6% Market Average Movement 6.3% 10% most volatile stocks in US Market 17.1% 10% least volatile stocks in US Market 3.1%
Stable Share Price: ATHA's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: ATHA's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer’s disease, as well as is in Phase 2 clinical trials to treat Parkinson’s disease dementia and Dementia with Lewy bodies. The company’s product pipeline includes ATH-1020, an orally available brain-penetrant small molecule designed to enhance the HGF/MET system that is in Phase 1 clinical trials to treat neuropathic pain and neurodegenerative diseases; and ATH-1105, an oral small molecule drug candidate, which is a preclinical model for the treatment of Amyotrophic Lateral Sclerosis.
Show more Athira Pharma, Inc. Fundamentals Summary How do Athira Pharma's earnings and revenue compare to its market cap? ATHA fundamental statistics Market cap US$20.96m Earnings (TTM ) -US$109.22m Revenue (TTM ) n/a
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) ATHA income statement (TTM ) Revenue US$0 Cost of Revenue US$0 Gross Profit US$0 Other Expenses US$109.22m Earnings -US$109.22m
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/26 08:36 End of Day Share Price 2024/12/24 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Athira Pharma, Inc. is covered by 9 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Esther Lannie Hong Berenberg Thomas Shrader BTIG Corinne Johnson Goldman Sachs
Show 6 more analysts 
